You are here

guselkumab

Janssen Touts Positive Mid-Late Stage Data From Two Ulcerative Colitis Trials

BioSpace

Mon, 10/10/22 - 10:52 am

ulcerative colitis

J&J's Tremfya approved, further crowding IL-inhibitor market

BioPharma Dive

Sat, 07/15/17 - 11:31 am

Interleukin-inhibitors

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

Endpoints

Thu, 07/13/17 - 05:38 pm

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab

Endpoints

Fri, 03/3/17 - 09:36 am

Here Are Johnson & Johnson's Next 10 Potential Blockbuster Drugs

Motley Fool

Wed, 11/2/16 - 10:00 am

This Looks to Be Johnson & Johnson's Next Blockbuster Drug

Motley Fool

Wed, 10/5/16 - 09:40 am

J&J psoriasis drug tops placebo, Humira in late stage study

Yahoo/Reuters

Mon, 10/3/16 - 09:42 pm

J&J chief touts $1B-plus prospects for coming psoriasis med guselkumab

Fierce Pharma Marketing

Wed, 07/15/15 - 11:27 am

Johnson & Johnson: Experimental drug clears more psoriasis patches than rival AbbVie's Humira

Yahoo/AP

Thu, 07/9/15 - 10:13 am

Experimental J&J psoriasis drug shows promise in study

Yahoo/Reuters

Sat, 03/22/14 - 12:10 pm